{"id":"nl003","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NL003 is an engineered interleukin-2 variant designed to preferentially bind and activate IL-2 receptors on T cells and NK cells while minimizing activation of regulatory T cells. This selective immune activation aims to enhance anti-tumor immunity with potentially improved tolerability compared to wild-type IL-2.","oneSentence":"NL003 is a recombinant human IL-2 mutein that selectively activates IL-2 receptor signaling to enhance immune cell proliferation and anti-tumor activity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:23:12.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07023965","phase":"","title":"Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Northland Biotech. Co., Ltd.","startDate":"2025-06-30","conditions":"Peripheral Arterial Disease(PAD), Arterial Occlusive Disease, Arteriosclerosis Obliterans","enrollment":542},{"nctId":"NCT04274049","phase":"PHASE3","title":"Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)","status":"COMPLETED","sponsor":"Beijing Northland Biotech. Co., Ltd.","startDate":"2019-08-28","conditions":"Arterial Occlusive Disease, Ischemia, Ulcers","enrollment":242},{"nctId":"NCT04275323","phase":"PHASE3","title":"Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)","status":"COMPLETED","sponsor":"Beijing Northland Biotech. Co., Ltd.","startDate":"2019-08-02","conditions":"Arterial Occlusive Disease, Ischemia, Ulcers","enrollment":302},{"nctId":"NCT05968118","phase":"PHASE3","title":"Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients","status":"UNKNOWN","sponsor":"Beijing Northland Biotech. Co., Ltd.","startDate":"2022-07-29","conditions":"Peripheral Artery Disease","enrollment":36},{"nctId":"NCT01548378","phase":"PHASE2","title":"Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia","status":"COMPLETED","sponsor":"Beijing Northland Biotech. Co., Ltd.","startDate":"2012-03","conditions":"Arterial Occlusive Disease, Ulcers, Ischemia","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HGF plasmid","pCK-HGF-X7"],"phase":"phase_3","status":"active","brandName":"NL003","genericName":"NL003","companyName":"Beijing Northland Biotech. Co., Ltd.","companyId":"beijing-northland-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NL003 is a recombinant human IL-2 mutein that selectively activates IL-2 receptor signaling to enhance immune cell proliferation and anti-tumor activity. Used for Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}